Michigan ADRC: Alzheimer’s Disease Research Focus (Updated March 2026)

Michigan ADRC: A Collaborative Leader in Alzheimer’s Disease Research (Updated March 2026)

Original Post Date: July 13, 2025 | Updated: March 2026

Michigan Alzheimer’s Disease Research Center (Michigan ADRC / MADC)

The Michigan Alzheimer’s Disease Research Center (Michigan ADRC), part of the national network of NIH-funded Alzheimer’s Disease Research Centers, stands out for its statewide collaboration among the University of Michigan (U-M), Michigan State University (MSU), and Wayne State University (WSU). This unique partnership creates a comprehensive resource for researchers, clinicians, trainees, and the public across Michigan, with a strong emphasis on Alzheimer’s disease and related dementias (ADRD)—including Lewy body dementia and vascular contributions—while prioritizing non-amyloid pathways, accessible biomarkers, neuroimaging, diversity, and community engagement.

Key Cores and Programs (building on the original strengths):

• University of Michigan Memory and Aging Project (UM-MAP): The center’s flagship longitudinal observational study tracks cognitive changes in adults 55+ (with or without impairment) to better understand normal aging versus neurodegenerative disease.
• Biomarker Core (MSU-led): Focuses on blood-based biomarkers for AD/ADRD to improve diagnosis, risk prediction, and inclusion of diverse populations—moving beyond amyloid to multiple dementia types.
• Neuroimaging Core: Uses advanced MRI and PET to examine transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer’s, with attention to neurovascular health, amyloid, tau, and neurodegeneration.
• Outreach, Recruitment, and Engagement (ORE) Core: Drives community education, tackles racial/ethnic disparities in research participation, and supports programs for underrepresented groups.
• Rinne Lewy Body Dementia Initiative: A designated Research Center of Excellence offering research, awareness, and support for Lewy body dementia patients and care partners.
• Additional strengths include the MiNDSet Registry (for matching participants to studies), the Michigan Brain Bank (brain donation program), and investigator support through pilot/developmental projects, Kickstarter Awards, and the Leaders Initiative Seminar Series (highlighting early-career researchers).

The center operates under the broader Michigan Alzheimer’s Disease Center (MADC) umbrella, based at U-M’s Department of Neurology, with clinical services at the Turner Geriatrics Center. It provides multidisciplinary care (neurologists, neuropsychologists, social workers), advanced diagnostics (PET, MRI, lumbar puncture), and navigation for emerging treatments.

Clinical Care and Community Support

Patients and families benefit from state-of-the-art evaluation to differentiate Alzheimer’s from other dementias, plus wellness and caregiver programs. Ongoing 2026 offerings include:

• Mitten Minds Support Group: Monthly for individuals with mild cognitive impairment or early-stage dementia (March–December 2026).
• Catching Your Breath: Monthly mindfulness and well-being program for family caregivers (January–December 2026).
• Have a Seat: Weekly virtual guided meditation.
• Lewy Body Dementia Support Groups: Virtual and in-person options (Ann Arbor, Boyne City, and others) running throughout 2026.
• Lived Experience Advisory Panel input, including reflections on social connection, blood pressure management for brain health, and caregiver journeys.

These programs reflect the center’s commitment to quality of life alongside research.

Broader Alzheimer’s Treatment and Research Landscape

No cure exists for Alzheimer’s, but approaches continue to evolve:

• Symptomatic Treatments: Cholinesterase inhibitors (e.g., donepezil) and memantine provide temporary cognitive support but do not alter disease course.
• Anti-Amyloid Therapies (lecanemab, donanemab): These modestly slow early-stage decline (~27% in trials) but come with high costs (~$26,000/year), side effects (ARIA—brain swelling/bleeding), and monitoring requirements. Real-world access, equity, and meaningful benefit remain active topics. Michigan researchers are actively studying feasibility in diverse and underserved communities, including Flint and Detroit.
• Tau-Targeted and Other Approaches: NIH’s Alzheimer’s Tau Platform Trial is slated to begin testing tau therapies (potentially late 2026). Lifestyle factors (exercise, diet, vascular health, blood pressure control) and non-amyloid pathways (inflammation, senescence, environmental risks) receive growing attention.
• Michigan’s “beyond amyloid” philosophy—emphasized by leaders like Director Henry Paulson—aligns well here: “Alzheimer’s is complicated and there’s much more to it than one molecule.” The center explores tau, vascular/neuroinflammation, epigenetics, environmental exposures (e.g., lead), and multi-modal biomarkers.

Other ADRCs vary in focus, but Michigan’s statewide reach, diversity efforts, and balanced portfolio set it apart.

Recent Developments (2025–2026)

Since the original post, the Michigan ADRC has maintained strong momentum:

• AAIC 2025 Contributions (Toronto): Researchers presented dozens of posters and talks covering diverse topics, including environmental risks (perinatal/residential lead exposure and oxidative stress/inflammation), epigenetics (DNA methylation age acceleration and dementia), tau pathways (Cdkn2a in tauopathy models; wild-type vs. mutant tau phosphorylation), caregiving (sandwiched caregivers’ well-being; Black dementia caregivers’ community support; living arrangements and care networks), the “obesity paradox” and cognitive decline, SuperAging Research Initiative (health behaviors in robust 80+/90+ year-olds), EEG/driving as potential biomarkers, and predictors of treatment optimism or cognitive transitions. These align closely with the center’s non-amyloid, diversity, and lifestyle emphases.
• Leaders Initiative: Monthly seminars spotlight early-career work. A notable upcoming session (March 27, 2026) features Dr. Melissa Elafros on “The Feasibility of Anti-Amyloid Therapy in Flint, Detroit, and Across the State”—directly addressing equity and real-world implementation of new treatments.
• Ongoing Funding and Support: The NIA P30 grant (P30AG072931) remains active through at least mid-2026, supporting pilot projects, mentorship (REC), and statewide collaboration. National increases in Alzheimer’s research funding (e.g., FY2026) provide a supportive backdrop.
• Wellness and outreach programs continue expanding into 2026, with emphasis on blood pressure/brain health links and social connection.

The center’s work on participant motivation in longitudinal studies, machine learning for biomarker prediction, and inclusive cohorts further strengthens translation from research to practice.

Key Differences and Strengths

Michigan ADRC excels in:

• Statewide collaboration and diversity focus.
• Balanced “beyond amyloid” research alongside practical biomarker and imaging tools.
• Robust community engagement and caregiver support.
• Training the next generation through seminars, pilots, and curricula.

Challenges remain universal—no cure, modest treatment benefits, cost/equity issues, and diagnostic gaps—but Michigan’s approach actively tackles them through inclusive science and real-world application.

How to Get Involved

• Join a Study: Participate in UM-MAP, register with MiNDSet, or explore other research opportunities at medresearch.umich.edu/labs-departments/centers/madc or call 734-936-8803.
• Brain Donation: Contribute via the Michigan Brain Bank (734-647-7648).
• Support Groups & Wellness: Sign up for Mitten Minds, Catching Your Breath, Lewy body groups, or Have a Seat meditation.
• Researchers: Apply for pilot funding, resources, or join the Leaders Initiative.
• Stay updated via the official site or email list.

Conclusion

The Michigan ADRC continues to distinguish itself as a collaborative, inclusive powerhouse in Alzheimer’s and related dementias research. Its emphasis on non-amyloid pathways, accessible diagnostics, equity, and community support complements global efforts like anti-amyloid and tau therapies—while addressing their limitations. With strong AAIC 2025 representation, active 2026 programs, and a clear focus on translating science into better lives, the center remains a vital resource for Michigan and beyond.

Research moves quickly—check the latest at the official Michigan ADRC pages (medresearch.umich.edu/labs-departments/centers/madc or alzheimers.med.umich.edu) or contact the team directly. If you or a loved one are affected by memory loss, reaching out can connect you to care, studies, or support.

This updated post draws from official University of Michigan sources and AAIC 2025 materials for the most current overview.

Original Post Date: July 13, 2025

The University of Michigan Alzheimer’s Disease Research Center (Michigan ADRC) focuses on a broad, multidisciplinary approach to Alzheimer’s disease and related dementias, emphasizing research, clinical care, education, and community outreach. Below, I outline the key aspects of Michigan ADRC’s work and compare it to other Alzheimer’s treatment and research approaches, based on available information and general knowledge about Alzheimer’s research. Since no definitive "cure" for Alzheimer’s exists, I’ll frame the comparison around research efforts, treatment strategies, and their limitations.

Michigan Alzheimer’s Disease Research Center (Michigan ADRC)

The Michigan ADRC, part of a network of 31 NIH-funded Alzheimer’s Disease Research Centers, is a collaborative effort involving the University of Michigan, Michigan State University, and Wayne State University. Its approach is distinctive in several ways:

1. Multidisciplinary and Statewide Collaboration:
   • Focus: The Michigan ADRC conducts research on Alzheimer’s and related dementias (e.g., Lewy body dementia, vascular dementia) with an emphasis on non-amyloid approaches, biomarkers, and underrepresented populations. It integrates efforts across three major Michigan universities, providing a statewide resource for researchers, clinicians, and the public.
   • Key Programs:
     • University of Michigan Memory and Aging Project (UM-MAP): A longitudinal study investigating cognitive changes over time in adults over 55, with or without cognitive impairment, to understand normal aging and neurodegenerative diseases.
     • Biomarker Core: Led by Michigan State University, this core focuses on blood-based biomarkers for Alzheimer’s and related dementias, aiming to improve diagnosis and include diverse populations.
     • Neuroimaging Core: Utilizes advanced MRI and PET imaging to study transitions from normal aging to mild cognitive impairment (MCI) and early Alzheimer’s, focusing on neurovascular health, amyloid, tau, and neurodegeneration.
     • Outreach, Recruitment, and Engagement (ORE) Core: Promotes community education, support groups (e.g., Mitten Minds for early-stage dementia), and wellness programs while addressing racial and ethnic disparities in research participation.
     • Rinne Lewy Body Dementia Initiative: Supports research, awareness, and care for Lewy body dementia, a related condition.
   • Unique Aspect: Unlike many ADRCs, Michigan’s center emphasizes non-amyloid pathways and collaborates across a statewide network, enhancing diversity in research and outreach.
2. Clinical Care and Support:
   • The Michigan ADRC, housed in the Turner Geriatrics Center, offers comprehensive care through a multidisciplinary team (neurologists, neuropsychologists, social workers, etc.) and uses advanced diagnostics like PET scans, MRI, and lumbar punctures to distinguish Alzheimer’s from other dementias.
   • It provides wellness programs (e.g., Catching Your Breath for caregivers) and support groups to improve quality of life for patients and families.
3. Research Goals:
   • The center investigates normal aging, mild cognitive impairment, and early Alzheimer’s, focusing on biomarkers, neuroimaging, and neuropathology (e.g., brain donation programs). It aims to develop novel diagnostic tools and treatments while addressing disparities in dementia care.

Other Alzheimer’s Treatment and Research Approaches

Current Alzheimer’s research and treatments globally focus on both symptomatic relief and disease-modifying therapies. No cure exists, but various strategies are being explored:

1. Symptomatic Treatments:
   • Cholinesterase Inhibitors (e.g., Donepezil, Rivastigmine) and Memantine: These FDA-approved drugs manage symptoms by addressing neurotransmitter imbalances (e.g., acetylcholine or glutamate). They improve cognitive function temporarily but do not slow disease progression.
   • Comparison to Michigan ADRC: Michigan ADRC’s clinical care likely incorporates these standard treatments as part of patient management, but its research prioritizes understanding disease mechanisms over symptomatic relief.
2. Anti-Amyloid Therapies:
   • Lecanemab and Donanemab: These monoclonal antibodies target amyloid-β plaques, a hallmark of Alzheimer’s. Clinical trials (e.g., lecanemab’s phase 3 trial) showed a 27% slower cognitive decline in early-stage Alzheimer’s patients over 18 months. However, they are expensive ($26,000/year for lecanemab), have side effects (e.g., brain swelling/bleeding), and require regular MRIs.
   • Challenges: These therapies are not curative, only modestly slow progression, and their clinical meaningfulness is debated. They also require early diagnosis, which can be challenging.
   • Comparison to Michigan ADRC: Michigan ADRC’s research de-emphasizes amyloid-centric approaches, focusing instead on non-amyloid pathways (e.g., tau, neurovascular health) and biomarkers for diverse dementia types. This broader scope may lead to complementary insights, as amyloid therapies alone may not suffice.
3. Tau-Targeted Therapies:
   • Research is exploring therapies targeting tau neurofibrillary tangles, another key Alzheimer’s pathology. For example, the NIH-supported Alzheimer’s Tau Platform Trial (starting late 2026) will test tau therapies alongside anti-amyloid drugs.
   • GSK-3 Inhibitors (e.g., Lithium, ANAVEX 2-73): These aim to prevent tau phosphorylation. Trials (e.g., ANAVEX 2-73 phase 2) show potential in improving daily activities but are not yet conclusive.
   • Comparison to Michigan ADRC: The Michigan ADRC’s Neuroimaging Core studies tau pathology via PET scans, and its research may contribute to tau-targeted therapy development, aligning with global efforts but with a focus on early detection and diverse populations.
4. Emerging Approaches:
   • Immunotherapy: Active immunotherapies like CAD106 target amyloid in preclinical Alzheimer’s, but past trials (e.g., early amyloid vaccines) failed due to side effects like brain inflammation
   • Gene Editing and Nanocarriers: Experimental approaches like gene editing or microneedle-based drug delivery aim to reduce amyloid and tau burdens but require significant research.
   • Lifestyle Interventions: Exercise, diet, and managing comorbidities (e.g., diabetes, hypertension) are studied to enhance brain health. These are not cures but may delay progression.
   • Comparison to Michigan ADRC: The Michigan ADRC’s Wellness Initiative and ORE Core promote lifestyle interventions (e.g., caregiver wellness programs) and study vascular contributions to dementia (e.g., WHISE study on hypertension). Its focus on social and environmental factors (via MCCFAD) aligns with these broader efforts but emphasizes community engagement and disparities.
5. Other ADRCs and Global Efforts:
   • Other NIH-funded ADRCs (e.g., Mayo Clinic, UC San Francisco, Yale) focus on similar goals but vary in emphasis. For example, UCSF prioritizes anti-amyloid and tau therapies, while Mayo Clinic studies brain aging broadly.
   • Comparison to Michigan ADRC: Michigan’s statewide collaboration and focus on non-amyloid pathways set it apart. Its Biomarker and Neuroimaging Cores emphasize novel diagnostic tools, and its ORE Core tackles disparities, which may not be as central at other centers.

Key Differences

• Scope and Collaboration: Michigan ADRC’s unique statewide partnership (U-M, MSU, WSU) fosters diverse research and outreach, unlike many ADRCs that operate within a single institution. Its non-amyloid focus contrasts with centers heavily invested in amyloid therapies.
• Diversity and Disparities: Michigan ADRC prioritizes underrepresented groups in research and care, addressing racial and ethnic disparities more explicitly than some other programs.
• Non-Amyloid Emphasis: While global research often centers on amyloid (e.g., lecanemab), Michigan ADRC explores broader pathways (e.g., tau, vascular health, biomarkers), potentially offering complementary insights.
• Community Engagement: Michigan’s ORE Core and wellness programs (e.g., Mitten Minds, Catching Your Breath) emphasize community support and education, which may be less prominent in treatment-focused research like anti-amyloid trials.
• Diagnostic Innovation: Michigan’s focus on biomarkers and neuroimaging (e.g., blood-based tests, PET scans) aims to improve early diagnosis, which is critical for therapies like lecanemab but also applicable to broader dementia types.

Limitations and Context

• No Cure Exists: Neither Michigan ADRC nor other research efforts have produced a cure. Michigan’s work, like others, focuses on understanding mechanisms, improving diagnostics, and slowing progression.
• Challenges in Translation: Anti-amyloid therapies show modest benefits but face issues like cost, side effects, and limited applicability to late-stage disease. Michigan’s broader approach may help address these gaps but is still in research phases.
• Need for Diversity: Global trials (e.g., lecanemab) struggle with diverse recruitment, a challenge Michigan ADRC actively addresses through its ORE Core and MCCFAD.

Conclusion

The Michigan ADRC stands out for its statewide collaboration, non-amyloid research focus, and emphasis on diversity and community engagement. While global efforts like anti-amyloid (lecanemab, donanemab) and tau-targeted therapies aim to slow Alzheimer’s progression, they are costly, have side effects, and offer modest benefits. Michigan’s work complements these by exploring novel biomarkers, neuroimaging, and lifestyle interventions, potentially paving the way for more inclusive and comprehensive strategies. However, like all Alzheimer’s research, it has not yet yielded a cure, and its impact depends on translating findings into practical treatments.

For more details on Michigan ADRC, visit https://alzheimers.med.umich.edu. For information on other Alzheimer’s treatments, check https://www.alzheimers.gov or https://www.nia.nih.gov.